Dergiler / Journal of Clinical Research in Pediatric Endocrinology / 2021 / Cilt: 13 - Sayı: 3

Evaluation of Growth Hormone Results in Different Diagnosis and Trend Over 10 Year of Follow-up: A Single Center Experience

Sayfa
332–341
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The improvement in the height SDS was most marked in the IGHD and MPHD groups, the least in the TS and SGA groups.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim was to evaluate the results of diagnosis, follow-up and treatment of the patients who recieved growth hormone (GH) treatment for the last 10 years and to determine the differences in the process and results over the years.
📊
Temel Bulgular & Veri:Methods: Anthropometric, clinical, laboratory data, treatment adherence and side effects were evaluated retrospectively in 767 patients who recieved GH treatment between 2009-2018.
💡
Sonuç & Katkı:The improvement in the height SDS was most marked in the IGHD and MPHD groups, the least in the TS and SGA groups.
🔬Tür:Araştırma Makalesi
📍Kapsam:2009-2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: The aim was to evaluate the results of diagnosis, follow-up and treatment of the patients who recieved growth hormone (GH) treatment for the last 10 years and to determine the differences in the process and results over the years. Methods: Anthropometric, clinical, laboratory data, treatment adherence and side effects were evaluated retrospectively in 767 patients who recieved GH treatment between 2009-2018. Patients were grouped as isolated GH deficiency (IGHD), multiple pituitary hormone deficiency (MPHD), small for gestational age (SGA), and Turner syndrome (TS) depending on diagnosis. Results: GH treatment was started in 689 cases (89.8%) with IGHD, 24 (3.1%) with MPHD, 26 (3.4%) with SGA and 28 (3.7%) with TS. Median age of GH treatment onset was the earliest in SGA (8.4 years) and the latest in the IGHD group (12.0 years). At the time of treatment cessation, height standard deviation score (SDS) in IGHD and MPHD was significantly higher than treatment initiation time, whereas there was no significant difference in TS and SGA. One hundred eighty-nine cases reached the final height. Final heights for girls/boys were: IGHD 154/164.9 cm; MPHD 156.2/163.5 cm; TS 146.7 cm; and SGA 145.7/-cm, respectively. Target height SDS-final height SDS median values were IGHD: 0.1, MPHD: 0.6, SGA: 0.5, TS: 2.4 respectively. The patients’ treatment compliance was high (92%) and the incidence of side effects was low (2.7%). Conclusion: In our cohort, GH treatment start age was late and no difference in this was observed in the last 10 years. The improvement in the height SDS was most marked in the IGHD and MPHD groups, the least in the TS and SGA groups.

🔖

Bu Makaleye Atıf Yap

AYCAN, Z., YILMAZ, A. A., YEL, S., ERDEVE, Ş., ÇETİNKAYA, S. (2021). Evaluation of Growth Hormone Results in Different Diagnosis and Trend Over 10 Year of Follow-up: A Single Center Experience. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 13 - Sayı: 3, 332–341. https://ajindex.com/articles/347703

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Ranke M, Wit J. Growth hormone-past, present and future. Nat Rev Endocrinol 2018
  2. Epub 2018 Mar 16 2. Collett-Solberg PF, Jorge AAL, Boguszewski MCS, Miller BS, Choong CSY, Cohen P, Hoffman AR, Luo X, Radovick S, Saenger P. Growth hormone therapy in children
  3. research and practice –a review. Growth Horm IGF Res 2019
  4. Epub 2018 Dec 26 3. Ranke MB, Lindberg A, Tanaka T, Camacho-Hübner C, Dunger DB, Geffner ME. Baseline characteristics and gender differences in prepubertal children treated with growth hormone in Europe, UAS, and Japan: 25 years’ KIGS experience (1987–2012) and review. Horm Res Paediatr 2017
  5. Epub 2016 Dec 3 4. Kaplowitz PB, Shulman DI, Frane JW, Jacobs J, Lippe B. Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS). Int J Pediatr Endocrinol 2013:9. 5. Polak M, Konrad D, Tønnes Pedersen B, BT Puras, Šnajderová M. Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet® International Outcome Study. J Pediatr Endocrinol Metab 2018
  6. Schoenfeld A, Redberg R. The value of using registries to evaluate randomized clinical trial study populations. JAMA Intern Med 2017
  7. Growth Hormone Research Society Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH research society. J Clin Endocrinol Metab 2000
  8. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Söderström- Anttila V, Stochholm K, van Alfenvan derVelden JA, Woelfle J, Backeljauw PF.
  9. International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017
  10. G1-G70. 9. Rosenfield RL, Cooke DW, Radovick S. Puberty and its disorders in the female. In: Sperling M, ed. Pediatric Endocrinology. 4th ed. Philadelphia, PA, Elsevier, 2014
  11. Neyzi O, Günoz H, Furman A, Bundak R, Gokcay G, Darendeliler F, Bas F. Weight, height, head circumference and body mass index references for Turkish children. Çocuk Sağlığı ve Hastalıkları Dergisi 2008
  12. Kurtoğlu S, Hatipoğlu N, Mazıcıoğlu MM, Akın MA, Çoban D, Gökoğlu S, B